Stay updated on IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded Locations section with Massachusetts and New York sites and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedUpdated the page to Revision: v3.3.2, replacing the previous v3.2.0. No core study information or documents were visibly changed.SummaryDifference0.1%

- Check52 days agoChange DetectedNotice about government funding and operating status was removed from the page; this change does not affect the study details, eligibility criteria, or user interactions with the trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check66 days agoChange DetectedUpdated the study record to include Results First Posted on 2025-05-15 and revised related dates. The page now shows new results information and updated status details.SummaryDifference0.4%

- Check95 days agoChange DetectedAdded a government-operating-status notice and new version v3.2.0; removed old version v3.1.0.SummaryDifference3%

- Check102 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.